Research group of China pharmaceutical innovation promotion association went to Germany for research
-
Last Update: 2015-07-15
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: China Association for the promotion of drugs July 13-15, 2015 in order to complete the drug policy related research project cooperated with Bayer company, song Ruilin, executive chairman of China Association for the promotion of drugs, led the research team to Germany to investigate the drug policy and medical insurance system in Germany Ms Lin Jing, vice president of public affairs and market access of Bayer healthcare Co., Ltd and others went together On July 13, the research team conducted a research in the German Pharmaceutical Industry Association (VFA) Harald Zimmer, head of VFA international affairs, received the research team Harald Zimmer first introduced the nature, organizational structure and main functions of VFA to the research team VFA is an industry association that promotes drug innovation At present, there are 45 pharmaceutical enterprises focusing on innovation, including both local enterprises and multinational companies Its main work includes policy and legislative lobbying in medicine, strengthening comparative research in health system, etc Research team investigates in VFA President Song Ruilin and head of VFA international affairs Harald Zimmer take a photo in VFA, from left to right: Chen Changxiong, Simone Bosch (head of Bayer headquarters market access), Hal Zimmer, song Ruilin, Lin Jing, Meike applath (Bayer headquarters market access Department), Hao Hu (Bayer China), Tina Orben (VFA) Oliver corff (translation) VFA specially invited Dr Jasmina, senior economist of Cologne Institute of economics, to make a theme report for the research group entitled "the impact of German pharmaceutical industry on German economy" Jasmina The main contents of the doctor's report are: the aging of population, the national attention to health and the transformation of economic development mode have a great impact on the development of the pharmaceutical industry; the development of German pharmaceutical industry is stable, little affected by the overall economic situation, and of great significance to the development of the national manufacturing industry and the national economy; the development and innovation of the pharmaceutical industry for the development of the entire economy It is of great significance to expand and improve labor productivity Tina Orben, manager of VFA in charge of market access and reimbursement policy research, introduced the German drug market access and reimbursement policy system to the research team In 2011, Germany promulgated and implemented the law on the reconstruction of drug market under the compulsory health insurance system The law mainly stipulates the procedures and methods of how to determine the reimbursement price of medical insurance through negotiation after the new drugs are put on the market In Germany, new drugs can be included in the list of medical insurance reimbursement after they are listed Before medical insurance institutions determine the price, enterprises can determine the price independently After the new drug is put on the market, the enterprise shall submit the evaluation materials to the Federal Joint Committee (GBA); GBA shall be submitted to the Institute of quality and benefit (IQWiG) for evaluation, and the latter shall evaluate its curative effect and economic benefit within three months, and after three months of hearing, those with new curative effect and economic benefit shall be submitted to GBA Conduct price negotiation with the enterprise for 6 months After price negotiation, reimbursement shall be made according to the negotiated price On the morning of July 14, the research team went to Bayer pharmaceutical headquarters for research Dr Florian, health policy representative of Bayer Medical Headquarters, introduced the origin, development and main contents of German medical insurance system in detail for the research group The medical insurance system in Germany originated from the social medical insurance law enacted in 1883 Its background is to establish a social insurance system in order to stabilize industrial workers under the general situation of the industrial revolution According to German law, citizens whose annual income does not exceed 54900 euros must take part in public medical insurance The insurance cost is 14.6% of the insured's income, which is borne by the employer and the insured Citizens with an annual income of more than 54900 Euros can choose to participate in public insurance or commercial medical insurance At present, 90% of German citizens participate in public health insurance, and the remaining 10% participate in commercial health insurance The public health insurance oversight body is the Federal Joint Commission (GBA), which is composed of representatives of physicians, psychologists, dentists, and the health insurance foundation The chairman of the committee is nominated by the Ministry of health and adopted by a special committee of the parliament The committee is responsible for the management of the medical insurance catalogue and the price negotiation of medical insurance drugs Dr David, manager of market access Department of Bayer Medical Headquarters, introduced the price negotiation procedure of medical insurance drugs in Germany, taking anti-tumor drugs as an example Before the new drugs of the enterprise enter into the price negotiation procedure of medical insurance, the manufacturer can consult the Federal Joint Committee (GBA) in two ways: one is to consult GBA in the phase II clinical trial stage to understand the principle of price negotiation and reference drugs, so as to adjust the clinical trial scheme in time Another situation is to consult GBA after the drug is put on the market The whole negotiation process is procedural, with little room for change First, the enterprise applies to GBA for efficacy value evaluation; GBA is submitted to IQWiG for evaluation The evaluation content is mainly to compare the efficacy, patient survival rate and adverse reaction rate of new drugs and existing drugs; the evaluation process and evaluation documents shall be open, and GBA shall hold a hearing; the final evaluation results shall be published on the website On the afternoon of July 14, the research team visited KKH company, a public health insurance institution Hogne Holm Heyder, head of the company's Berlin office, briefed the research team on the company's main businesses and the way public health insurance companies operate He pointed out that the medical insurance fund is mainly used to pay for hospitalization, outpatient medical services and medicine Medical service charges are mainly charged according to the type of disease After the medical insurance reimbursement price of drugs is determined by GBA, the manufacturer shall provide it to the wholesaler, and then the wholesaler shall provide it to the drugstore, and the medical insurance fund shall settle with the wholesaler; the wholesaler shall guarantee the supply of drugs The research group conducted a research in KKH company Through this research in Germany, the research group has a detailed understanding of Germany's medical insurance system, procedures for new drugs to enter the medical insurance reimbursement, procedures for medical insurance drug price negotiation, etc These contents have certain reference significance for the development of new drugs and the improvement of medical insurance system in China
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.